Physician profile
Abhay Dhand
NPI 1851407712
$200,523.14
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $25K · 2021: $12K · 2022: $9,472 · 2023: $14K · 2024: $7,808 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $7,585 · Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $12,147.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,265.00 |
| Consulting Fee | $7,585.00 |
| Food and Beverage | $1,169.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $107,632.04 | 2019-2025 | Prevymis, Zerbaxa |
| Tetraphase Pharmaceuticals, INC. | $60,294.70 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $21,366.21 | 2019-2025 | Nuzyra, Xhance |
| La Jolla Pharmaceutical Company | $6,040.81 | 2022-2024 | Xerava |
| Astellas Pharma US INC | $1,883.74 | 2019-2022 | |
| Allergan, INC. | $1,569.45 | 2019 | |
| Shionogi INC | $1,319.88 | 2019 | |
| Eurofins Viracor, LLC | $173.05 | 2024 | |
| Invivyd INC | $111.27 | 2025 | Pemgarda |
| Melinta Therapeutics, LLC | $96.17 | 2019 | |
| Astellas Pharma Global Development | $35.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhay Dhand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.